A new class of drug for pulmonary arterial hypertension. Can a Rho-kinase inhibitor break the stagnation in treating it?

Circ J. 2013;77(10):2477-8. doi: 10.1253/circj.cj-13-0951. Epub 2013 Aug 9.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / administration & dosage
  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / analogs & derivatives*
  • Female
  • Hemodynamics / drug effects*
  • Humans
  • Hypertension, Pulmonary*
  • Lung / blood supply*
  • Male
  • Protein Kinase Inhibitors / administration & dosage*
  • rho-Associated Kinases / antagonists & inhibitors*

Substances

  • Protein Kinase Inhibitors
  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
  • rho-Associated Kinases
  • fasudil